[SCHEDULE 13G/A] Cyclacel Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Report overview: This Schedule 13G/A states that Kua Khai Loon beneficially owns 805,695 shares of Bio Green Med Solution, Inc. common stock, representing 16.35% of the class. The filing breaks ownership into 338,160 common shares and warrants totaling 467,535 (218,000 Series A warrants, 218,000 Series B warrants, and 31,535 Series C warrants) that are exercisable into common stock.

The filer certifies the shares were not acquired to change or influence control. The document lists the issuer's Kuala Lumpur address and the reporter's Malaysian residence, and it attaches warrant forms as exhibits.

Positive

• Sole voting and dispositive power over 805,695 shares provides clear, centralized ownership
• Disclosure includes warrant details (Series A, B, C totaling 467,535) improving transparency

Negative

• Concentrated ownership at 16.35% could increase stock volatility if the holder trades
• Potential dilution from 467,535 warrants may reduce current holders' percentages if exercised

Insights

Corporate Governance Analyst

Insider ownership of 16.35% signals a meaningful minority stake with voting control concentrated in one holder.

The filing documents that Kua Khai Loon directly holds 805,695 shares and multiple warrants convertible into common stock, giving combined economic exposure to the company’s equity. Concentration of sole voting and dispositive power is explicit and identifies a single influential holder.

Risks include potential dilution if warrants are exercised and the holder's future transactions may affect float and voting dynamics; monitor warrant exercise timelines and any subsequent amendments near 09/12/2025 and filings that update percent ownership.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Bio Green Med Solution, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

23254L876

(CUSIP Number)

09/12/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 23254L876

1

Names of Reporting Persons

Kua Khai Loon

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MALAYSIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 805,695.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 805,695.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

805,695.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

16.35 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The reporting person's ownership consists of (i) 338,160 shares of common stock, (ii) 218,000 series A warrants to purchase shares of common stock, (iii) 218,000 series B warrants to purchase shares of common stock, and (iv) 31,535 series C warrants to purchase shares of common stock (the series A warrants, series B warrants and series C warrants, collectively, the "Warrants")

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Bio Green Med Solution, Inc.
(b)	Address of issuer's principal executive offices: Level 10, Tower 11, Avenue 5, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia 59200
Item 2.
(a)	Name of person filing: Kua Khai Loon
(b)	Address or principal business office or, if none, residence: NO 28 JALAN EKOFLORA 1/13 TAMAN EKOFLORA JOHOR BAHRU 81100 JOHOR MALAYSIA
(c)	Citizenship: Malaysia
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 23254L876
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 805,695
(b)	Percent of class: 16.35%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 805,695
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 805,695
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Kua Khai Loon

Signature:	/s/ Kua Khai Loon
Name/Title:	Kua Khai Loon
Date:	10/10/2025

Exhibit Information

Form of Amended and Restated Series A Common Stock Warrant Form of Amended and Restated Series B Common Stock Warrant Form of Amended and Restated Series C Common Stock Warrant sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-1.htm sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-2.htm sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-3.htm sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-4.htm

FAQ

How many shares of BGMS does Kua Khai Loon report owning?

The filing reports 805,695 shares beneficially owned.

What percentage of BGMS does that represent?

The reported stake equals 16.35% of the outstanding common stock.

Does the filing disclose warrants that could increase ownership?

Yes. It discloses 218,000 Series A, 218,000 Series B, and 31,535 Series C warrants convertible into common stock.

Did the filer state an intent to influence control of BGMS?

No. The filer certified the securities were not acquired to change or influence control of the issuer.

Where is the issuer headquartered according to the filing?

The issuer’s principal executive offices are listed in Kuala Lumpur, Malaysia.